APYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIALBy ApyxMedical|2025-12-12T19:06:56-05:00February 21, 2023|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023By ApyxMedical|2025-12-12T19:07:24-05:00February 16, 2023|
RENUVION COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON ‘THE BALANCING ACT’ TALK SHOW ON LIFETIME FEBRUARY 13By ApyxMedical|2025-12-12T19:07:54-05:00February 9, 2023|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTIONBy ApyxMedical|2025-12-12T19:08:24-05:00February 1, 2023|
APYX MEDICAL CORPORATION LAUNCHES NEW ‘APYX ONE CONSOLE’ FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATESBy ApyxMedical|2025-12-12T19:10:24-05:00January 25, 2023|
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE RESULTSBy ApyxMedical|2025-12-12T19:11:04-05:00January 10, 2023|
APYX MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVIONBy ApyxMedical|2025-12-12T19:11:47-05:00January 3, 2023|
